<DOC>
	<DOCNO>NCT01567306</DOCNO>
	<brief_summary>Based EMA ( European Medicines Agency ) new guideline clinical development product immunotherapy treatment allergic disease aim study establish dose-response relationship clinical efficacy Phleum pratense pollen extract subcutaneous vaccine .</brief_summary>
	<brief_title>Phase II Trial With Subcutaneous Immunotherapy Patients Sensitized Phleum Pratense</brief_title>
	<detailed_description>In adherence EMA guideline , Phase I Clinical trial carry use Phleum pratense extract depot presentation use 3 different dose escalation scheme . The objective compare tolerance safety three dose escalation scheme well determine maximum dose tolerate population . Once range tolerate dos establish , follow strict norm EMA , Phase II dose response clinical trial design wherein efficacy subcutaneous immunotherapy depot presentation could compare 5 different dos . One dose MTD establish population first study , another low dose , three great . The dose escalation scheme test chosen base result aforementioned clinical trial . As dictated EMA norm , control placebo use .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>1 . Patients must sign Informed Consent Form . 2 . Patients must 18 60 year age . 3 . Patients seasonal allergic rhinoconjunctivitis produce Phleum pratense least 2 year prior participate study . Although pathology study allergic rhinoconjunctivitis , patient concomitant mild moderate asthma may include . 4 . Patients skin prick test result equal 3 mm diameter Phleum pratense . 5 . Patients specific IgE equal class 2 ( CAP/PHADIA ) Phleum pratense . 6 . Patients preferably monosensitized Phleum pratense . Polysensitized patient may include study sensitization produce : Overlapping seasonal pollen crossreactive Phleum pratense . Pollens whose season overlap Phleum pratense expect produce symptom study period . Other allergen expect produce symptom study period . 7 . Women childbearing potential must negative urine pregnancy test time begin study . 8 . Furthermore , woman childbearing potential must agree use adequate contraceptive method study sexually active . 1 . Patients stable continue use allergy medication 2 week prior inclusion study . 2 . Patients sensitize allergen overlap season crossreactive Phleum pratense specific IgE level equal less class 2 CAP/PHADIA . 3 . Patients receive immunotherapy 5 year prior study either allergen test allergen crossreactive , currently receive immunotherapy allergen . 4 . Patients severe asthma FEV1 &lt; 70 % asthma require treatment inhaled systemic corticoid time study 8 week immediately prior onset treatment . 5 . Patients immunological , cardiac , renal hepatic disease illness investigator deem may interfere study . 6 . Patients prior history anaphylaxis . 7 . Patients chronic urticaria . 8 . Patients moderatesevere atopic dermatitis . 9 . Patients clinically relevant malformation upper respiratory tract . 10 . Patients participate another clinical trial within 3 month prior study . 11 . Patients treat tricyclic antidepressant , psychotropic drug , betablockers , angiotensinconverting enzyme inhibitor ( ACEIs ) . 12 . Women pregnant breastfeed childbearing age agree use adequate contraception sexually active demonstrate surgically sterilize mean bear child . 13 . Patients attend study visit . 14 . Patients uncooperative refuse participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
	<keyword>Subcutaneous Immunotherapy</keyword>
	<keyword>Phleum pratense pollen extract</keyword>
</DOC>